TopStocks Alert: (NASDAQ: COSM) Why Cosmos Health Inc. Has Landed On Our Radar And The 8 Catalysts Behind It
Hello Readers,
A company just guided to triple its revenue by 2029. It posted the highest quarterly revenue in its history. An independent research firm pegs fair value at $4.50. And the stock? It is sitting at $0.28.
One of those things does not belong. That is exactly why COSM landed at the top of our screen.
What has management been doing while the stock sat here?
- Issuing 2026 to 2029 guidance targeting $200.6 million in revenue and a swing to net profitability by 2027.
- Launching a clinically validated nutraceutical platform into the U.S. market.
- Securing an advisory agreement with the European Investment Bank for a potential 50 million euro R&D program.
- Posting 31% revenue growth year over year.
- Reducing total liabilities by $4.5 million in a single quarter.
- Signing a third consecutive reorder from one of the UAE's largest pharmacy distributors.
The activity does not match the price. That gap is why COSM landed at the top of our screen. Here is what is driving it.
Why COSM Is On Our Radar Right Now
- No. 1 — Fresh 2026 to 2029 guidance targets $200.6M in revenue, a 207% increase, with net profitability projected by 2027 and gross margin expanding to 35.5%.
- No. 2 — Record Q1 2026 revenue of $17.93M, up 31% year over year, while liabilities drop $4.5M and stockholders' equity rises.
- No. 3 — 18 Series platform formally launched in the U.S. — a certification standard that most supplement companies cannot clear.
- No. 4 — Fort18 enters the U.S. men's wellness market, backed by a published RCT showing a 5.1-fold improvement in endurance over placebo.
- No. 5 — Cur18 and Liv18 add two more U.S. revenue ramps with combined management projections of over $10.7M in incremental annual revenue.
- No. 6 — Third consecutive Pharmalink purchase order brings cumulative UAE units to 270,000, advancing a 5-year goal of 3 million units.
- No. 7 — EIB advisory agreement opens the door to up to 25 million euros in non-dilutive or minimally dilutive institutional financing.
- No. 8 — Zacks Small-Cap Research values COSM at $4.50 per share using DCF analysis against a current price near $0.28.
But more on those in a moment...
Company Breakdown — Cosmos Health Inc. (NASDAQ: COSM)
Diversified, Vertically Integrated Global Healthcare Platform
Founded in 2009 and incorporated in Nevada, Cosmos Health is a diversified, vertically integrated global healthcare group. The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands including Sky Premium Life, Mediterranation, bio-bebe, C-Sept, and C-Scrub. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices and certified by the European Medicines Agency, it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union.
Cosmos Health distributes a broad line of pharmaceuticals and parapharmaceuticals through its Greek and UK subsidiaries, including CosmoFarm. The company also operates an emerging AI-assisted drug development pipeline targeting oncology, weight management, and other high-value therapeutic areas. The company is led by CEO Greg Siokas, who has been executing a pivot from traditional pharmaceutical distribution toward a higher-margin, branded nutraceutical and pharmaceutical development platform anchored in the United States.
Multiple Operating Pillars Create A Broader Growth Story
Cosmos Health is not a one-dimensional story. The company operates across pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands, and AI-assisted drug development. That breadth matters because it creates multiple ways to generate revenue, and increasingly, multiple ways to generate higher-margin revenue as branded products grow as a share of the overall mix.
The three primary operating pillars are CosmoFarm in Greece, which handles pharmaceutical distribution and added over 75 new pharmacies in Q1 2026 alone; Cana Laboratories, an EMA-certified manufacturing subsidiary that now serves contract manufacturing customers alongside the company's own brands; and Sky Premium Life, a proprietary nutraceutical brand with distribution across the UAE, Greece, the UK, and other markets. The new fourth pillar is the 18 Series, the company's U.S.-facing branded nutraceutical platform and the most strategically significant growth driver in the near term.
Full-year 2025 revenue was $65.3 million, up from $54.4 million in 2024. Q1 2026 revenue of $17.93 million set a new quarterly record, coming in 31% above Q1 2025. Management's newly released guidance projects full-year 2026 revenue of more than $90 million and full-year 2029 revenue of $200.6 million, with a swing from a 2025 net loss to projected net income of $31.0 million by 2029. The 18 Series platform targets U.S. health categories where the combined addressable market already exceeds $7.8 billion across the products introduced so far.
1. Fresh Multi-Year Guidance Lays Out A Path To $200 Million In Revenue And A Swing To Profitability.
On May 26, 2026, Cosmos Health released formal financial guidance for the 2026 to 2029 period, and the numbers reframe the entire story. Management is targeting revenue of $200.6 million by 2029, up from $65.3 million in 2025, a 207% increase at a 32% compound annual growth rate. The company expects to surpass $90 million in revenue in 2026 alone, roughly 38% year-over-year growth, with the climb continuing each year through 2029.
The quality of that growth is the part that stands out. Gross profit is guided to rise from $7.9 million in 2025 to $71.2 million in 2029, with gross margin expanding from 12.1% to 35.5% as higher-margin proprietary products and contract manufacturing take a larger share of the mix. Management projects a swing from a 2025 net loss of $19.1 million to net income of $31.0 million by 2029, with net profitability expected to arrive in 2027. Adjusted EBITDA is guided from a $3.4 million loss to a $44.2 million gain over the same window, and non-diluted EPS is projected to reach $0.73 by 2029.
The balance sheet picture is just as notable. Management expects operating cash flow to turn positive in 2027 and reach $24.0 million by 2029, cash to climb roughly 18-fold to $62.9 million, all convertible notes to be repaid, and the company to carry a negative net debt position by 2027. CEO Greg Siokas described the company as being at a critical inflection point and noted he purchased over 3.3 million shares in 2025, with continued buying in 2026.
2. Record Q1 2026 Revenue And A Strengthening Balance Sheet Show The Platform Is Working.
On May 21, 2026, Cosmos Health reported record Q1 2026 revenue of $17.93 million, up 31% year over year from $13.71 million in Q1 2025, and up 34% on an adjusted basis to $18.4 million. Revenue growth was broad-based across all core divisions. CosmoFarm added over 75 new pharmacies in the quarter. Sky Premium Life order activity grew across multiple markets. Cana Laboratories added new contract manufacturing agreements. At the same time, total liabilities fell $4.5 million, or 9.6%, in a single quarter, driven by reductions in convertible note and credit facility balances. Stockholders' equity rose $1.4 million, or 7.6%, and the liabilities-to-assets ratio improved by 370 basis points to 68.2%. Adjusted EBITDA was near breakeven.
3. The 18 Series Is A Certification Standard That Most Supplement Companies Cannot Clear.
On April 21, 2026, Cosmos Health formally introduced the 18 Series in the United States. The supplement industry is saturated with products backed by nothing more than marketing language. The 18 Series is built around the opposite approach. Every product must clear three defined criteria before it earns the designation: a patented active ingredient, published peer-reviewed clinical evidence, and dosing at the exact amount used in that published research. Most supplement brands on retail shelves cannot satisfy even one of those three requirements. That creates a potential competitive moat in a market where consumers are increasingly demanding scientific credibility. The platform currently has three introduced products targeting a combined U.S. addressable market of more than $7.8 billion, backed by seven or more peer-reviewed published studies and three patented active ingredients.
4. Fort18 Enters A $1.93 Billion U.S. Addressable Market With Published Clinical Data Behind It.
On May 6, 2026, Cosmos Health introduced Fort18 in the United States, the latest addition to the 18 Series. Fort18 is a men's sexual stamina supplement formulated with a proprietary five-ingredient botanical blend backed by a published randomized, double-blind, placebo-controlled study of 60 participants. That study reported a 5.1-fold improvement in endurance versus placebo over eight weeks, with onset observed as early as Week 4. The U.S. sexual health supplement market was estimated at $965.8 million in 2023 and is projected to reach $1.93 billion by 2030, according to Grand View Research. On May 11, 2026, the company separately projected that Fort18 could generate more than $3.2 million in incremental annual revenue in the United States within 12 to 18 months.
5. Cur18 And Liv18 Add Layered U.S. Revenue Ramps Across Curcumin And Liver Health Categories.
Beyond Fort18, Cosmos Health has been building out the 18 Series pipeline with additional U.S. launches. On April 30, 2026, the company projected that Cur18, its curcumin supplement, could generate more than $2.5 million in incremental annual revenue in the United States within 12 to 18 months, with a U.S. launch planned for Q2 2026. Separately, on April 20, 2026, the company said that Liv18, its liver health supplement, had completed Phase 1 production with sales commencing in April 2026, and projected more than $5 million in annual revenue from that product at approximately 75% gross margins. The projected revenue contributions from Fort18, Cur18, and Liv18 represent more than $10.7 million in potential incremental annual U.S. revenue across three products.
6. A Third Consecutive Pharmalink Purchase Order Validates The Sky Premium Life Brand In One Of The World's Most Competitive Wellness Markets.
On April 13, 2026, Cosmos Health announced its third consecutive purchase order from Pharmalink for 60,000 units of Sky Premium Life products under an exclusive distribution agreement for the United Arab Emirates market. Cumulative orders since June 2024 have now reached 270,000 units. The trajectory tells the story: Pharmalink placed an initial order of 130,000 units at launch. After that inventory sold through completely, Pharmalink followed with 80,000 units in May 2025. The latest 60,000-unit order is the third consecutive reorder, demonstrating sustained commercial demand rather than one-time stocking activity. Pharmalink is one of the largest healthcare organizations in the UAE, with approximately 1,400 employees, a portfolio of over 430 brands, and access to more than 3,000 pharmacies including its own MEDICINA chain of approximately 200 locations. The company has set a target of surpassing 3 million cumulative units over the first five years of the partnership.
7. The EIB Advisory Agreement Opens The Door To Potentially Transformative Non-Dilutive Institutional Financing.
On May 14, 2026, Cosmos Health announced that subsidiary Cana Laboratories had entered into an advisory agreement with the European Investment Bank to pursue financing support for a planned 50 million euro R&D initiative. Under the EIB's venture debt framework, the potential financing could cover up to 50% of the program, or approximately 25 million euros. The EIB is one of Europe's premier institutional lenders and typically conducts extensive due diligence before engaging. While the financing is not guaranteed and remains milestone-dependent, the advisory agreement itself represents an important validation of the company's R&D ambitions.
8. Zacks Small-Cap Research Values COSM At $4.50 Per Share Using DCF Analysis, Against A Current Price Near $0.28.
In a May 21, 2026 sponsored research report, Zacks Small-Cap Research maintained its $4.50 per share DCF-based valuation on Cosmos Health, with the stock trading at approximately $0.28 on the date of the report. Zacks SCR is compensated by the issuer for the preparation of this type of report. With that context noted, the underlying analysis projects full-year 2026 revenue of $87.3 million and full-year 2027 revenue of $110.8 million. On the earnings line, Zacks projects the company to reach profitability in Q2 2026 with EPS of $0.01, moving to $0.02 in Q3 and $0.04 in Q4. Insider ownership stands at 25% and institutional ownership at 13%. The stock's 52-week high is $1.25 against a current price near $0.28.
(NASDAQ: COSM) Recap — 8 Catalysts
- No. 1 — New 2026 to 2029 guidance targets $200.6M in revenue by 2029, a 207% increase at a 32% CAGR; gross margin expanding to 35.5%; net profitability projected in 2027 with $31.0M in net income by 2029; cash projected to reach $62.9M with all convertible notes repaid.
- No. 2 — Record Q1 2026 revenue of $17.93M, up 31% year over year; total liabilities down $4.5M in a single quarter; stockholders' equity up 7.6%; adjusted EBITDA near breakeven.
- No. 3 — 18 Series platform launched in the U.S. with a three-part certification standard most supplement companies cannot clear. Targeting 18 products across a combined $7.8B+ U.S. addressable market.
- No. 4 — Fort18 enters the U.S. men's wellness market, backed by a published RCT showing a 5.1-fold endurance improvement. Management projects more than $3.2M in incremental annual U.S. revenue within 12 to 18 months.
- No. 5 — Cur18 and Liv18 add layered U.S. revenue ramps. Combined management projections across three 18 Series products exceed $10.7M in potential incremental annual U.S. revenue.
- No. 6 — Third consecutive Pharmalink reorder for 60,000 Sky Premium Life units brings cumulative UAE orders to 270,000 units, advancing a 5-year goal of 3 million units.
- No. 7 — EIB advisory agreement through Cana Laboratories opens potential access to up to 25 million euros under a 50 million euro venture debt framework.
- No. 8 — Zacks Small-Cap Research sponsored research report maintains $4.50 DCF valuation with the stock near $0.28; projects $87.3M in 2026 revenue and $110.8M in 2027; insider ownership at 25%.
Cosmos Health Inc. (NASDAQ: COSM) has landed on our radar in a big way. We are watching closely. Updates to follow.
Sincerely,
TopStocks.com